Dear [Name],

I am writing to respond to your request sent on the 21st June 2016. OUH can confirm that it holds the data that you requested.

1. What is the composition of the multi-disciplinary team for dermatology in the Trust? **Consultants, Nurses, Pathologists, Oncologists.**

2. How many dermatology consultants work within the Trust? **7.4wte**

3. How many speciality dermatology nurses work within the Trust (including dermatology clinical nurse specialists and dermatology nurse practitioners)? **6.5wte**

4. Does the Trust have standards to support healthcare professionals to deliver psychodermatological care? **No**

5. How many adult patients with Atopic Dermatitis (ICD-10-CM Diagnosis Code L20.9) have been referred for psychological support by the specialised dermatology multi-disciplinary team? **None**

6. Does your Trust produce local guidelines to support the management of adult Atopic Dermatitis (L20.9)? (yes / no) **No**

7. What is the ‘Friends and Family Test’ score for the Trust’s dermatology services? **100%**

8. What is the average time to treatment from referral for adults with Atopic Dermatitis (L20.9) in the Trust? 96% of Dermatology patients are treated within 18 weeks. **This information is not broken down at diagnosis level, The Trust is unable to provide this information.**

9. How many dermatology outpatient appointments occurred between 1st January and 31st December 2015 in your Trust for adult patients with diagnosed or suspected Atopic Dermatitis (L20.9) in each of the following categories: **The Trust is not able to provide this information. There no diagnosis codes at outpatient level.**
   a. first attendance – single professional
   b. first attendance – multi-professional
   c. follow up attendance – single professional
   d. follow up attendance – multi-professional

10. If data on the number of dermatology outpatient appointments in your Trust for adult patients with diagnosed or suspected Atopic Dermatitis is not available for the period 1st January to 31st December 2016, please provide the most recent summary data available for each of the following categories: **The Trust measures activity using a calendar year and not financial year. Therefore unable to provide information**
for a time that has not completed yet. The information provided below is based on financial year 2015/16 as follows:

a. first attendance – single professional 5281
b. first attendance – multi-professional 171
c. follow up attendance – single professional 7805
d. follow up attendance – multi-professional. 374

11. Please outline which of the following treatments are available to adult patients with Atopic Dermatitis (L20.9) in the Trust, according to the local formulary.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Yes/No</th>
<th>Available as a first line treatment option for appropriate adult patients with Atopic Dermatitis (yes/no)</th>
<th>Available as a second line treatment option for appropriate adult patients with Atopic Dermatitis (yes/no)</th>
<th>Available as a third line treatment option for appropriate adult patients with Atopic Dermatitis (yes/no)</th>
<th>Other (please indicate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emollients</td>
<td>y</td>
<td>y</td>
<td>y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Topical steroids (corticosteroids)</td>
<td>y</td>
<td>y</td>
<td>y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-histamines</td>
<td>y</td>
<td>y</td>
<td>y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic steroids</td>
<td>y</td>
<td>y</td>
<td></td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Topical calcineurin inhibitors</td>
<td>y</td>
<td>y</td>
<td></td>
<td>y</td>
<td></td>
</tr>
<tr>
<td>Oral immunosuppressants</td>
<td>n</td>
<td>y</td>
<td></td>
<td>y</td>
<td></td>
</tr>
<tr>
<td>Phototherapy</td>
<td>y</td>
<td>y</td>
<td></td>
<td>y</td>
<td></td>
</tr>
</tbody>
</table>
Please note that on 1 November 2011 the Oxford Radcliffe Hospitals NHS Trust (ORH) merged with the Nuffield Orthopaedic Hospital NHS Trust (NOC) to form the Oxford University Hospitals NHS Trust (OUH). Our response reflects these changes. Therefore, we consider that Oxford University Hospitals Trust has released to you all of the information that it holds in relation to your request.

Yours sincerely,

From: [Redacted]
Sent: 21 June 2016 18:13
Subject: Freedom of Information Request to Trust

Dear Freedom of Information Officer,

I am writing to you on behalf [Redacted] Please find below a request for information on your Trust’s dermatology services. I would be grateful if you could provide the answers to these questions within the time frame specified by the Freedom of Information Act 2000.

Kind regards,

QUESTIONS:

1. What is the composition of the multi-disciplinary team for dermatology in the Trust?

2. How many dermatology consultants work within the Trust?

3. How many speciality dermatology nurses work within the Trust (including dermatology clinical nurse specialists and dermatology nurse practitioners)?

4. Does the Trust have standards to support healthcare professionals to deliver psychodermatological care?

5. How many adult patients with Atopic Dermatitis (ICD-10-CM Diagnosis Code L20.9) have been referred for psychological support by the specialised dermatology multi-disciplinary team?

6. Does your Trust produce local guidelines to support the management of adult Atopic Dermatitis (L20.9)? (yes / no)

7. What is the ‘Friends and Family Test’ score for the Trust’s dermatology services?

8. What is the average time to treatment from referral for adults with Atopic Dermatitis (L20.9) in the Trust?
9. How many dermatology outpatient appointments occurred between 1st January and 31st December 2015 in your Trust for adult patients with diagnosed or suspected Atopic Dermatitis (L20.9) in each of the following categories:
   a. first attendance – single professional
   b. first attendance – multi-professional
   c. follow up attendance – single professional
   d. follow up attendance – multi-professional

10. If data on the number of dermatology outpatient appointments in your Trust for adult patients with diagnosed or suspected Atopic Dermatitis is not available for the period 1st January to 31st December 2016, please provide the most recent summary data available for each of the following categories:
   a. first attendance – single professional
   b. first attendance – multi-professional
   c. follow up attendance – single professional
   d. follow up attendance – multi-professional.

11. Please outline which of the following treatments are available to adult patients with Atopic Dermatitis (L20.9) in the Trust, according to the local formulary.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Yes / No</th>
<th>Available as a first line treatment option for appropriate adult patients with Atopic Dermatitis (yes/no)</th>
<th>Available as a second line treatment option for appropriate adult patients with Atopic Dermatitis (yes/no)</th>
<th>Available as a third line treatment option for appropriate adult patients with Atopic Dermatitis (yes/no)</th>
<th>Other (please indicate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emollients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topical steroids (corticosteroids)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-histamines</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic steroids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topical calcineurin inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral immuno-suppressants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phototherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>